Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy

• DOI: 10.1016/j.ejca.2012.02.003
• Publication Date: 2012-03-08T14:00:32Z
• Authors: T. Van der Kwast; N. Al Daoud; L. Collette; J. Sykes; J. Thoms; M. Milosevic; R.G. Bristow; G. Van Tienhoven; P. Warde; R.-O. Mirimanoff; M. Bolla
• Keywords: Male; Biopsy; Clinical progression; Kaplan-Meier Estimate; Disease-Free Survival; Cohort Studies; Metastatic disease; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Humans; Hormone therapy; Intraductal carcinoma; Aged; Aged, 80 and over; Prostate cancer; Radiotherapy; Intermediate risk; Prostatic Neoplasms; Middle Aged; Prognosis; ResearchInstitutes_Networks_Beacons/mcrc; name=Manchester Cancer Research Centre; 3. Good health; Carcinoma, Intraductal, Noninfiltrating; Treatment Outcome; Neoplasm Grading; Follow-Up Studies

We investigated the prognostic significance of intraductal carcinoma of the prostate (IDC-P) in biopsies and transurethral resections prior to external beam radiotherapy with or without androgen deprivation.Cohort 1 consisted of 118 intermediate risk prostate cancer patients treated by radiotherapy, with biochemical relapse as primary end-point (median follow-up 6.5 years). Cohort 2 consisted of 132 high risk patients, enrolled in a phase III randomised trial (EORTC 22863) comparing radiotherapy alone to radiotherapy with long-term androgen deprivation (LTAD) with clinical progression free survival as primary end-point (median follow-up 9.1 years). Presence of IDC-P was identified after central review. Multivariable regression modelling and Kaplan-Meier analysis were performed with IDC-P as dichotomous variable.IDC-P was a strong prognosticator for early (<36 months) biochemical relapse (HR 7.3; p = 0.007) in cohort 1 and for clinical disease-free survival in both arms of cohort 2 (radiotherapy arm: HR 3.5; p < 0.0001; radiotherapy plus LTAD arm: HR 2.8, p = 0.018). IDC-P retained significance after stratification for reviewed Gleason score in the radiotherapy arm (HR 2.3; p = 0.03). IDC-P was a strong prognosticator for metastatic failure rate (radiotherapy arm: HR 5.3; p < 0.0001; radiotherapy plus LTAD arm: HR 3.6; p = 0.05).IDC-P in diagnostic samples of patients with intermediate or high risk prostate cancer is an independent prognosticator of early biochemical relapse and metastatic failure rate after radiotherapy. We suggest that the presence of IDC-P in prostate biopsies should routinely be reported.